MG29

MG29 is a recombinant protein therapeutic being developed by TRIM-edicine for the treatment of aging-related muscle disorders, including sarcopenia and age-related muscle dysfunction. MG29 (Mitsugumin 29) is a skeletal muscle-specific protein belonging to the synaptophysin family, localized to the membrane of the transverse tubule (T-tubule) where it plays a critical role in maintaining calcium homeostasis and muscle structural integrity. Research has shown that MG29 expression levels decrease by approximately 50% in aged skeletal muscle, a downregulation linked to muscle aging phenotypes such as fragmented sarcoplasmic reticulum, T-tubule swelling, and increased susceptibility to fatigue. By restoring MG29 levels, the therapeutic aims to address calcium signaling defects and enhance muscle repair capacity in elderly individuals.

Other names

Mitsugumin 29Mitsugumin29Mitsugumin-29recombinant MG29